Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 3
2013 1
2015 1
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection.
Jacobson JM, Zheng L, Wilson CC, Tebas P, Matining RM, Egan MA, Eldridge J, Landay AL, Clifford DB, Luetkemeyer AF, Tiu J, Martinez AL, Janik J, Spitz TA, Hural J, McElrath J, Frahm N; ACTG A5281 Protocol Team. Jacobson JM, et al. J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):163-71. doi: 10.1097/QAI.0000000000000830. J Acquir Immune Defic Syndr. 2016. PMID: 26761518 Free PMC article. Clinical Trial.
Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.
Taiwo BO, Chan ES, Fichtenbaum CJ, Ribaudo H, Tsibris A, Klingman KL, Eron JJ, Berzins B, Robertson K, Landay A, Ofotokun I, Brown T; AIDS Clinical Trials Group A5303 Study Team. Taiwo BO, et al. Clin Infect Dis. 2015 Oct 1;61(7):1179-88. doi: 10.1093/cid/civ455. Epub 2015 Jun 9. Clin Infect Dis. 2015. PMID: 26060295 Free PMC article. Clinical Trial.
The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit.
Wohl DA, Kendall MA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Benson C, Keiser P, van der Horst C, Jacobson MA; A5030 Study Team. Wohl DA, et al. PLoS One. 2013 Nov 15;8(11):e78676. doi: 10.1371/journal.pone.0078676. eCollection 2013. PLoS One. 2013. PMID: 24260125 Free PMC article. Clinical Trial.
Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants.
Grady BJ, Torstenson ES, McLaren PJ, DE Bakker PI, Haas DW, Robbins GK, Gulick RM, Haubrich R, Ribaudo H, Ritchie MD. Grady BJ, et al. Pac Symp Biocomput. 2011:253-64. doi: 10.1142/9789814335058_0027. Pac Symp Biocomput. 2011. PMID: 21121053 Free PMC article. Clinical Trial.
Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.
Wohl DA, Kendall MA, Andersen J, Crumpacker C, Spector SA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Lurain N, Jabs D, Benson C, Keiser P, Jacobson MA; A5030 Study Team. Wohl DA, et al. HIV Clin Trials. 2009 May-Jun;10(3):143-52. doi: 10.1310/hct1003-143. HIV Clin Trials. 2009. PMID: 19632953 Free PMC article. Clinical Trial.